Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Huizenga sold 1,283 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $13.57, for a total transaction of $17,410.31. Following the sale, the chief accounting officer owned 67,863 shares of the company’s stock, valued at approximately $920,900.91. The trade was a 1.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Theodore Alan Huizenga also recently made the following trade(s):

• On Thursday, September 3rd, Theodore Huizenga sold 161 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $13.99, for a total transaction of $2,252.39.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $13.07 on Wednesday. The company’s fifty day moving average price is $25.10 and its 200-day moving average price is $24.63. Ultragenyx Pharmaceutical Inc. has a 1-year low of $12.88 and a 1-year high of $39.89. The firm has a market capitalization of $1.29 billion, a P/E ratio of -2.24 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the firm posted ($1.17) earnings per share. The firm’s quarterly revenue was up 28.5% on a year-over-year basis. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the topic of a number of recent research reports. Citigroup lowered their target price on Ultragenyx Pharmaceutical from $58.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. William Blair downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Thursday, September 3rd. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Canaccord Genuity Group cut their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating for the company in a report on Thursday, September 3rd. Finally, TD Cowen lowered their price target on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. BlackRock Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $355,746,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $6,397,000. Deutsche Bank AG purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $5,503,000. Corient Private Wealth LP purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $4,644,000. Finally, Blue Owl Capital Holdings LP acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $6,098,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.